Susmita Roy

Susmita Roy

Auto-generated profile, based on publicly available information

Susmita Roy

Chettinad Hospital and Research Institute (CHRI)

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2025 in Epigenetics
Verified
Journal Article
Open access
SRSusmita Roy
Susmita Roy
DDDikshita Deka
Dikshita Deka
SKSuresh Kondaveeti
Suresh Kondaveeti
PAPavithra Ayyadurai
Pavithra Ayyadurai
SSSravani Siripragada
Sravani Siripragada
Antara BanerjeeAntara Banerjee
Antara Banerjee
Colorectal cancer (CRC) remains an alarming global health concern despite advancements in treatment modalities over recent decades. Among the various factors contributing to CRC, this review emphasizes the critical role of epigenetic mechanisms in its pathogenesis and progression. This review also describes the potential role of natural compounds in altering the epigenetic landscape, focused mainly on DNA methylation, histone modification, and non-coding RNAs. Publications from the previous five years were searched and retrieved using well-known search engines and databases like PubMed, Google Scholar, and ScienceDirect. Keywords like CRC/colorectal cancer, CAC/Colitis associated CRC, inflammasomes, epigenetic modulation, genistein, curcumin, quercetin, resveratrol, anthocyanins, sulforaphane, and epigallocatechin-3-gallate were used in various combinations during the search. These natural compounds predominantly affect pathways such as Wnt/β-catenin, NF-κB, and PI3K/AKT to suppress CRC cell proliferation and oxidative stress and enhance anti-inflammation and apoptosis. However, their clinical use is restricted due to their low bioavailability. However, multiple methods exist to overcome challenges like this, including but not limited to structural modifications, nanoparticle encapsulations, bio-enhancers, and novel advanced delivery systems. These methods improve their potential as supportive therapies that target CRC progression epigenetically with fewer side effects. Current research focuses on enhancing epigenetic targeting to control CRC progression while minimizing side effects, emphasizing improved specificity, bioavailability, and efficacy as standalone or synergistic therapies.

15 April 2025 in Journal of Molecular Structure
Verified
Journal Article
Closed access
TBTirtha Bhattacharjee
Tirtha Bhattacharjee
SNSourav Nath
Sourav Nath
TSTanushree Sen
Tanushree Sen
KNKeerthi Nethaji
Keerthi Nethaji
AFAmeena Farhana
Ameena Farhana
SASuman Adhikari
Suman Adhikari